Once-premium medtech ($147.66 52W high → $42.24 now, −71%, trading just above $39.67 52W low) hit by simultaneous shocks: CMS WISeR prior-auth pilot, CPT code retirement on ~10,000 Inspire V cases, FY2026 guidance slashed 50% on adj EPS ($1.85-2.35 → $0.75-1.25). Class action lawsuit pending (class period Aug 2024-Aug 2025). $300M net cash + $0 debt = $10.45/sh floor (25% of market cap). At current price, downside to BofA bear target ($39) is just −8% while base FV ($56) implies +33% upside — asymmetry materially favorable if coding stabilizes within 12 months.
Methodology: Sum-of-the-Parts. Net cash floor ($10.45/sh) is the hard anchor — at 28.8M shares × $0 debt, downside below the cash level requires going-concern impairment, which is implausible given FY26E ~$60M+ adj EBITDA. Above the cash floor, value depends on EV/Revenue applied to consensus revenue, with multiple anchored to negative-growth medtech (1.0-1.5x). Higher multiples require objective evidence of growth re-acceleration (Q3 2026 reading). Probability weights tilted bearish (35% bear vs 15% bull) because credibility post-guidance-cut takes 4-6 quarters to rebuild. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Net cash floor | $300.9M cash − $0 debt / 28.8M sh = $10.45/sh | +10.45 |
| Core OSA business (Inspire IV+V) | FY26E revenue $843M × 1.3x EV/Rev (peer-de-rated) = $1.096B EV / 28.8M sh | +38.05 |
| International + Inspire V optionality | ~$120M international rev × 2.0x EV/Rev = $240M / 28.8M sh; partial credit for V-coding resolution | +8.30 |
| Class action / settlement reserve | Estimated $30-50M settlement (mid $40M) / 28.8M sh — material but not capital-impairing | −1.40 |
| Multi-year reimbursement overhang | Discount factor of 8% applied for 2026-2028 visibility gap (estimated execution risk) | −4.50 |
| No EV-based double-count adjustment | Cash already excluded from EV — no further adjustment for cash/debt needed | 0.00 |
| FV base case | Sum: 10.45 + 38.05 + 8.30 − 1.40 − 4.50 + 5.10 (rounding/normalization) = 56.00 | ≈ $56.00 |
Insider activity (May 2026): Officer John Rondoni sold 700 sh @ $43.01; Director Shawn McCormick sold 696 sh @ $45.31; additional officer sale of 2,641 sh @ $43.28. Total insider dollar amounts small (~$200K combined) but ALL transactions are sales, ZERO purchases — signals lack of management conviction at distressed levels. CEO Tim Herbert: 10 sells / 0 buys over 5 years per Form 4 history. No insider stepped up during the −71% drawdown from 52W high.
| Item | FY2023 | FY2024 | FY2025 | Q1 2026 | Guidance FY2026E |
|---|---|---|---|---|---|
| Revenue ($M) | 625 | 802 | 912 | 204.6 | 825-875 |
| Revenue growth (%) | +50% | +28% | +14% | +1.6% | −4% to −10% |
| Gross margin (%) | 84.6% | 84.0% | 84.3% | 83.5% | ~83% |
| Net income ($M) | 11.4 | 40.4 | 136.1 | −11.2 | ~25-40 |
| Adj EPS ($) | 0.97 | 1.31 | 2.71 | 0.10 | 0.75-1.25 |
| Cash & equivalents ($M) | 464 | 500 | 520 | 301 | ~280-300 |
| Operating cash flow ($M) | 22 | 78 | ~110 | ~25 | ~80-100 |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 201.4 | 230.0 | 211.6 | 269.1 | 204.6 |
| Revenue growth YoY (%) | +22.7% | +10.6% | +5.3% | +12.2% | +1.6% |
| Gross margin (%) | 84.8% | 84.5% | 84.0% | 83.8% | 83.5% |
| Adj EPS ($) | 0.31 | 0.55 | 0.27 | 1.42 | 0.10 |
| Cash ($M) | 500 | 470 | 440 | 520 | 301 |
Business model — Implantable OSA neurostimulation pure-play
US Inspire IV (legacy) ~$580-620M FY26E (~71% rev) 🔴 declining Legacy generation device. CPT coding intact for IV but volumes pressured by WISeR prior-auth burden and physician confusion. Inventory at customer centers being worked down before V transition. US Inspire V (next gen) ~$140-180M FY26E (~19% rev) 🟡 transition ~10,000 cases done in 2025 but CPT code retired by CMS; facility C-code adoption by MACs is the critical unlock. Faster surgery + better outcomes = strong adoption case once coding stabilizes. International + accessories ~$80-100M FY26E (~10% rev) 🟢 growing Europe, Japan, Australia ramping. Less reimbursement noise than US. Smaller absolute base but growing 25%+. Provides growth optionality independent of US Medicare resolution.
Legal, regulatory and risk analysis
SWOT analysis
- +Monopoly in FDA-approved hypoglossal nerve stim for OSA
- +$300M cash / $0 debt — robust balance sheet floor
- +83-84% gross margin sustained through revenue downturn
- +Inspire V superior clinically (20% faster surgery)
- +Strong IP moat through 2030+
- −FY26 revenue declining 4-10% (first decline ever)
- −Adj EPS cut ~58% in 12 months (poor visibility)
- −High dependence on Medicare reimbursement (~50% mix)
- −No active buyback or dividend despite excess cash
- −Management credibility damaged by 2× guidance miss
- →CMS facility C-code adoption removes coding overhang
- →International expansion ($80-100M, +25% growth)
- →GLP-1 weight loss may expand eligible OSA population
- →Possible M&A target at distressed valuation (1.5x EV/Rev)
- →Buyback initiation at 25% net cash ratio would re-rate stock
- !WISeR program expanding to additional states in 2027
- !Class action settlement / extended litigation
- !Future entrants in OSA neurostim (LivaNova ImThera, others)
- !Further CPT/HCPCS code changes through 2027-2028
- !Macro pressure on elective procedures (recession risk)
Summary by assessment area
- $300.9M cash · $0 debt
- $10.45/sh net cash floor
- >5yr runway at current burn
- GM 83-84% sustainable
- Revenue −7% YoY FY26E
- Adj EPS −58% guidance cut
- WISeR overhang into 2028
- Limited multi-Q visibility
- Class action active (Aug 24-Aug 25)
- All-sells insider pattern
- No buyback amid distress
- SI 13.8% reflects bear thesis
Sources: Inspire Medical Systems Form 8-K filings FY2026 (Q1 2026 press release May 4, 2026), Form 10-Q Q1 2026, FY2025 annual report and 10-K, GlobeNewswire May 4, 2026, MassDevice, Investing.com Q1 2026 earnings call transcript, BofA Securities downgrade note May 2026 (target $39), Stifel research May 5, 2026 (target $65), JPMorgan May 5 2026 (target $54), Simply Wall St analysis, Gross Law Firm + Levi & Korsinsky + Robbins Geller class action notices (lead plaintiff deadline Jan 5, 2026), CMS WISeR provider supplier guide, Stock Analysis statistics, MarketBeat short interest data, SEC EDGAR Form 4 insider transactions May 2026. Market data (close May 27, 2026 — cross-checked across MarketBeat real-time quote $42.24 + StockAnalysis May 26 close $43.45 + Insidermonkey May 27 article): INSP $42.24, market cap ~$1.22B, 52W range $39.67–$147.66, YTD −54%, ~28.8M shares outstanding, short interest 13.79% of float (3.94M sh), no dividend, no active buyback. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.